ASCO 2013 Report — Breast Cancer

A review of the latest treatment regimens

At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2013), held May 31 through June 5 in Chicago, specialists discussed the latest findings in cancer research. The editors of Journal Watch Oncology and Hematology were in attendance to report highlights of the conference. Here, Editor-in-Chief William Gradishar, MD, reviews presentations on new breast cancer treatments.

Longer-Duration Tamoxifen Therapy Is Beneficial

The standard duration of adjuvant tamoxifen therapy for patients with estrogen receptor (ER)–positive breast cancer has been 5 years since follow-up of the NSABP B-14 trial (J Natl Cancer Inst 2001; 93:684) showed that longer durations of the ER inhibitor tamoxifen were associated with statistically in…

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)